- Home
- PVLA vs ARCT Comparison
PVLA vs ARCT Comparison
Compare PVLA & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PVLA
- ARCT
- Stock Information
- Founded
- PVLA 2015
- ARCT 2013
- Country
- PVLA United States
- ARCT United States
- Employees
- PVLA N/A
- ARCT N/A
- Industry
- PVLA Biotechnology: Pharmaceutical Preparations
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- PVLA Health Care
- ARCT Health Care
- Exchange
- PVLA Nasdaq
- ARCT Nasdaq
- Market Cap
- PVLA 249.2M
- ARCT 298.3M
- IPO Year
- PVLA N/A
- ARCT N/A
- Fundamental
- Price
- PVLA $25.92
- ARCT $13.78
- Analyst Decision
- PVLA Strong Buy
- ARCT Strong Buy
- Analyst Count
- PVLA 7
- ARCT 8
- Target Price
- PVLA $46.29
- ARCT $52.83
- AVG Volume (30 Days)
- PVLA 129.2K
- ARCT 474.9K
- Earning Date
- PVLA 08-15-2025
- ARCT 08-04-2025
- Dividend Yield
- PVLA N/A
- ARCT N/A
- EPS Growth
- PVLA N/A
- ARCT N/A
- EPS
- PVLA N/A
- ARCT N/A
- Revenue
- PVLA N/A
- ARCT $143,680,000.00
- Revenue This Year
- PVLA N/A
- ARCT N/A
- Revenue Next Year
- PVLA N/A
- ARCT $34.79
- P/E Ratio
- PVLA N/A
- ARCT N/A
- Revenue Growth
- PVLA N/A
- ARCT 15.38
- 52 Week Low
- PVLA $11.17
- ARCT $8.04
- 52 Week High
- PVLA $29.27
- ARCT $25.88
- Technical
- Relative Strength Index (RSI)
- PVLA N/A
- ARCT 54.34
- Support Level
- PVLA N/A
- ARCT $13.10
- Resistance Level
- PVLA N/A
- ARCT $15.20
- Average True Range (ATR)
- PVLA 0.00
- ARCT 1.02
- MACD
- PVLA 0.00
- ARCT 0.07
- Stochastic Oscillator
- PVLA 0.00
- ARCT 55.21
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.